Is Guardant Health (GH) Stock Outpacing Its Medical Peers This Year?

Group 1 - Guardant Health (GH) has significantly outperformed the Medical sector in 2023, with a year-to-date return of approximately 246.8% compared to the sector's average return of 7% [4] - The Zacks Rank for Guardant Health is currently 2 (Buy), indicating a positive outlook based on earnings estimates and revisions [3] - The Zacks Consensus Estimate for GH's full-year earnings has increased by 3.7% over the past quarter, reflecting improving analyst sentiment [3] Group 2 - Guardant Health is part of the Medical - Biomedical and Genetics industry, which consists of 467 stocks and is currently ranked 77 in the Zacks Industry Rank [5] - The average return for stocks in the Medical - Biomedical and Genetics industry this year is 20%, indicating that Guardant Health is performing better than its peers [5] - Another notable stock in the Medical sector, Collegium Pharmaceutical (COLL), has a year-to-date return of 67% and is ranked 1 (Strong Buy) in the Zacks Rank [4][5]